Estimation of Bioavailability of Salmon Calcitonin from the Hypocalcemic Effect in Rats (I): Pharmacokinetic-Pharmacodynamic Modeling Based on the Endogenous Ca Regulatory System

Drug Metabolism and Pharmacokinetics

Volumn 18, Issue 6, 2003, Pages 350-357

  Miyazaki, Makoto ^a   Nakade, Susumu ^a   Iwanaga, Kazunori ^a   Kakemi, Masao ^a   Morimoto, Kazuhiro ^b  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

calcium regulation; feedback control; hypocalcemic effect; PK PD model; salmon calcitonin

Indexed keywords

EID: 78651362518     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.18.350     Document Type: Article

References (26)

1. Meyer, J. P., Pelton, J. T., Hoflack, J. and Saudek, V.: Solution structure of salmon calcitonin. Biopolymers, 31: 233-241 (1991).
2. Reginster, J. Y., Jeugmans-Huynen, A. M., Wouters, M., Sarlet, N., McIntyre, H. D. and Franchimont, P.: The effect of nasal hCT on bone turnover in Paget's disease of bone-implications for the treatment of other metabolic bone diseases. Br. J. Rheumatol., 31: 35-39 (1992).
3. Thamsborg, G., Storm, T. L., Sykulski, R., Brinch, E., Nielsen, H. K. and Sorensen, O. H.: Effect of different doses of nasal salmon calcitonin on bone mass. Calcif. Tissue Int., 48: 302-307 (1991).
4. Hirai, S., Yashiki, T., Matsuzawa, T. and Mima, H.: Absorption of drugs from nasal mucosa of rats. Int. J. Pharm., 9: 317-325 (1981).
5. Zhou, X. Z. and Li Wan Po, A.: Comparison of enzymic activities of tissues lining portals of drug absorption, using the rat as a model. Int. J. Pharm., 62: 259-267 (1990).
6. Hussain, A. A., Iseki, K., Kagoshima, M. and Dittert, L. W.: Hydrolysis of peptides in the nasal cavity of humans. J. Pharm. Sci., 79: 947-948 (1990).
7. Morimoto, K., Miyazaki, M. and Kakemi, M.: Effects of proteolytic enzyme inhibitors on nasal absorption of salmon calcitonin in rats. Int. J. Pharm., 113: 1-8 (1995).
8. Nakada, Y., Miyake, M. and Awata, N.: Some factors affecting the vaginal absorption of human calcitonin in rats. Int. J. Pharm., 89: 169-175 (1993).
9. Saito, Y., Yasuhara, M., Okumura, K. and Hori, R.: High molecular weight derivative of salmon calcitonin with prolonged hypocalcemic activity. J. Pharm. Sci., 74: 345-347 (1985).
10. Lee, K. C., Soltis, E. E., Newman, P. S., Burton, K. W., Mehta, R. C. and DeLuca, P. P.: In vivo assessment of salmon calcitonin sustained release from biodegradable microspheres. J. Controlled Release, 17: 199-206 (1991).
11. Haussler, M. R., Mangelsdorf, D. J., Komm, B. S., Terpening, C. M., Yamaoka, K., Allegretto, E. A., Baker, A. R., Shine, J., McDonnell, D. P., Hughes, M., Weigel, N. L., O'Malley, B. W. and Wesleypike, J.: Molecular biology of the vitamin D hormone. Recent. Prog. Horm. Res., 44: 263-305 (1988).
12. Kronenberg, H. M., Lanske, B., Kovacs, C. S., Chung, U. I., Lee, K., Segre, G. V., Schipani, E. and Juppner, H.: Functional analysis of the PTH/PTHrP network of ligands and receptors. Recent. Prog. Horm. Res., 53: 283-303 (1988).
13. Hochhaus, G. and Derendorf, H.: Dose optimization based on pharmacokinetic-pharmacodynamic modeling. In Derendorf, H. and Hochhaus, G. (eds): Handbook of Pharmacokinetic, Pharmacodynamic Correlation, CRC Press Inc., Boca Raton, 1995, pp. 79-120.
14. Buck, R. H. and Maxl, F.: A validated HPLC assay for salmon calcitonin analysis. Comparison of HPLC and biological assay. J. Pharm. Biomed. Anal., 8: 761-769 (1990).
15. Bucht, E., Granberg, B., Sjöstedt, U. and Torring, O.: A rapid extraction method for serum calcitonin. Clin. Chim. Acta., 195: 115-124 (1991).
16. Lu, W., Endoh, M., Katayama, K., Kakemi, M. and Koizumi, T.: Pharmacokinetic and pharmacodynamic studies of piretanide in rabbits. I. Effect of different hydrated conditions. J. Pharmacobio-Dyn., 10: 356-363 (1987).
17. Lausson, S., Tracqui, P., Toubiana, L., Milhaud, G., Perault-Staub, A. M. and Staub, J. F.: Regulation of plasma calcium and phosphate in calcitonin-infused rats. Am. J. Physiol., 259: E370-E377 (1990).
18. Torres, A., Rodriguez, M., Felsenfeld, A., Martin-Malo, A. and Llach, F.: Sigmoidal relationship between calcitonin and calcium: studies in normal, parathyroidectomized, and azotemic rats. Kidney Int., 40: 700-704 (1991).
19. Staub, J. F., Tracqui, P., Brezillon, P., Milhaud, G. and Perault-Staub, A. M.: Calcium metabolism in the rat: a temporal self-organized model. Am. J. Physiol., 254: R134-R149 (1988).
20. Herfarth, K., Drechsler, S., Imhoff, W., Schlander, M., Engelbach, M., Maier, A. and Schmidt-Gayk, H.: Calcium regulating hormones after oral and intravenous calcium administration. Eur. J. Clin. Chem. Clin. Biochem., 30: 815-822 (1992).
21. Segre, G., Bruni, G. and Dal Pra, P.: Calcitonin pharmacokinetics, In Pecile, A. (ed.): Calcitonin, Excerpta Medica, Amsterdam, 1985, pp. 99-107.
22. Wendelaar Bonga, S. E. and Pang, P. K.: Control of calcium regulating hormones in the vertebrates: parathyroid hormone, calcitonin, prolactin, and stan-niocalcin. Int. Rev. Cytol., 128: 139-213 (1991).
23. Nichols, A. I., Boudinot, F. D. and Jusko, W. J.: Second generation model for prednisolone pharmacodynamics in the rat. J. Pharmacokinet. Biopharm., 17: 209-227 (1989).
24. Mager, D. E. and Jusko, W. J.: Receptor-mediated pharmacokinetic/pharmacodynamic model of inter-feron-beta 1a in humans. Pharm Res., 19: 1537-1543 (2002).
25. McDermott, M. T. and Kidd, G. S.: The role of calcitonin in the development and treatment of osteoporosis. Endocr. Rev., 8: 377-390 (1987).
26. Patel, S., Lyons, A. R. and Hosking, D. J.: Drugs used in the treatment of metabolic bone disease. Drugs, 46: 594-617 (1993).